Clinical trials: Skin Tests
Breast Cancer, Preneoplastic Conditions, BRCA
A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old
The purpose of this study is to measure the performance of the ForeCYTE Breast Aspirator for the collection and processing of Nipple Aspirate Fluid (NAF) specimens for cytology.
- Trial name
- NCT02539615
- Testing
- ForeCYTE Breast Aspirator
- Where
- 2 sites in Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Skin Irritation
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
Human repeat insult patch test to assess the potential for Cetaphil Moisturizing Lotion Daily Advance to induce sensitization to the skin
- Trial name
- NCT01892423
- Testing
- Cetaphil Moisturizing Lotion Daily Advance
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Hypersensitivity
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
In this study researcher want to learn more about possible skin reactions such after repeated application of an antifungal cream containing Trolamine. They are especially interested in skin irritations or allergic skin reactions.
- Trial name
- NCT04531540
- Testing
- Butenafine HCl 1% (BAY1896425)
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Bayer
Type I Hypersensitivity
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00104390
- Testing
- Grass MATA MPL
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Allergy Therapeutics
Allergy
Development and Evaluation of an Artificial Intelligence Model for the Diagnosis of Aeroallergies
To improve accuracy and take out human error, Hippo Dx previously developed S.P.A.T., an automated skin prick test. Now, Hippo Dx will develop and evaluate a S.P.A.T.
- Trial name
- SPAT_AI (NCT05918354)
- Testing
- Skin Prick Automated Test
- Where
- 6 sites in Belgium, Germany
- Volunteers
- 993 people
- Sponsor
- Hippocreates
Intact Skin
Open-Label Test of the HM242 Medical Devices to Evaluate Safety and Local Tolerability
It is the first clinical study aimed at assessing the safety and tolerability of HM242-Solution and HM242-Gel after their application under occlusion on intact skin. The HM242-Solution is intended for chronic wounds (e.g.
- Trial name
- NCT04192123
- Testing
- HM242
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- B. Braun Ltd. Centre of Excellence Infection Control
Adenocarcinoma, Gastric, Neoplasm, Breast
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03368196
- Testing
- DS-8201a
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Rheumatoid Arthritis
Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)
The primary objective of this study is to assess the number of patients preferring the methotrexate pre-filled pen to the methotrexate pre-filled syringe after 6 weeks of treatment based on a questionnaire
- Trial name
- NCT01793259
- Testing
- methotrexate prefilled pen, methotrexate prefilled syringe
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- medac GmbH
Skin Care
To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
The aim of this study is to assess irritant or allergic response of 3 developmental cosmetic facial products following a conventional human repeated insult patch test methodology for 6 weeks.
- Trial name
- NCT04007159
- Testing
- Serum, Lotion, Cream
- Where
- Brazil
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Irritation
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
Determine if Cetaphil Restoraderm Skin Restoring Body Wash proves to be a contact sensitizer or irritant in certain individuals.
- Trial name
- NCT01892410
- Testing
- Cetaphil Restoraderm Skin Restoring Body Wash
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Plague, Plague, Bubonic
Yersinia Pestis Lateral Flow Immunoassay for Blood Samples
Plague is a deadly but highly treatable disease caused by the bacterium Y. pestis. Due to the historical development of Y. pestis as a bioweapon by several nation states, it is listed by the US as a potential bioweapon that could…
- Conditions
- Plague, Plague, Bubonic, Plague, Pneumonic, Yersinia Pestis Plague
- Trial name
- SMARTPRT (NCT04688996)
- Testing
- Lateral Flow Assay for Pathogens of the Plague
- Where
- 2 sites in United States, Madagascar
- Volunteers
- 500 people
- Sponsor
- Brimrose Technology Corporation
Breast Cancer, Metastatic, Breast Cancer Invasive
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
- Conditions
- Breast Cancer, Metastatic, Breast Cancer Invasive, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- PROBE-CTC (NCT06807502)
- Testing
- The DM/DIV ScreenCell is the experimental product studied during this research
- Where
- France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- ScreenCell
Allergy Skin, Allergy
NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test
The objective of this study is to investigate the potential of NeoMatriXTM Wound Matrix to cause an allergic response to healthy volunteers using a skin prick test.
- Conditions
- Allergy Skin, Allergy, Dermatitis, Allergic Contact
- Trial name
- NCT03522675
- Testing
- NeoMatriX Wound MatriX Collagen Dressing
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- NeXtGen Biologics, Inc.
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Allergy Pollen
Microassay and Allergy Skin Prick Test Correlation Study
The purpose of this study is to evaluate the potential correlation of the results of allergen-specific skin prick tests (SPT) to that of allergen-specific microarray determination (microassay test).
- Trial name
- NCT03514303
- Testing
- Spiriplex Allergenex Microassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- United Allergy Services
Irritation/Irritant, Sensitisation
Human Skin Safety Testing of 1 Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers
The objective of this study is to investigate the irritation and sensitization potential of 1 topically applied test article containing Mitopure in a shared panel of healthy volunteers by means of repeated cutaneous patch…
- Trial name
- GLOW-Safety-4 (NCT07517874)
- Testing
- Mitopure Topical Formula 11
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Amazentis SA
Allergy
Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing
A Phase III study to determine the sensitivity and specificity of three solutions of different allergen extracts for diagnosis by skin prick-test: 5 Grasses pollen, Birch pollen, Dermatophagoides pteronyssinus mite
- Trial name
- NCT01964768
- Testing
- Skin prick-test
- Volunteers
- 324 people
- Sponsor
- Stallergenes Greer
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Neoplasms, Breast Neoplasms
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
This is a study in adult patients with different types of cancer. The purpose of this study is to find a safe dose of: Xentuzumab in combination with abemaciclib Xentuzumab in combination with abemaciclib and hormonal therapies…
- Trial name
- NCT03099174
- Testing
- Xentuzumab, Abemaciclib, Letrozole
- Where
- 30 sites in United States, Denmark and 5 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim